FourThought Financial’s BioMarin Pharmaceuticals BMRN Stock Holding History

FourThought Financial’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	$36K	Buy	421 +266	+172%	+$23.7K	0.01%	702
2022 Q2	$13K	Sell	155 -204	-57%	-$16.2K	﹤0.01%	955
2022 Q1	$12K	Sell	359 -408	-53%	-$34.1K	﹤0.01%	1005
2021 Q4	$68K	Sell	767 -212	-22%	-$17.5K	0.01%	577
2021 Q3	$75K	Buy	979 +199	+26%	+$15.7K	0.01%	565
2021 Q2	$65K	Buy	780 +26	+3%	+$2.06K	0.01%	622
2021 Q1	$56K	Sell	754 -33	-4%	-$2.7K	0.01%	656
2020 Q4	$69K	Buy	+787	New	+$62.4K	0.01%	579

Other funds holding BMRN

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

FourThought Financial's BMRN Position: Q3 2022 in Review

FourThought Financial increased its BioMarin Pharmaceuticals (BMRN) stake by 172% in Q3 2022, buying an estimated $23.7K and bringing the position to 421 shares worth $36K. The position accounts for 0.01% of the portfolio, ranked #702.

FourThought Financial first reported a position in BMRN in Q4 2020 and has held it in 8 quarters since. The position peaked at $75K in Q3 2021. 552 funds tracked by Wall St. Rank hold BMRN as of Q3 2022.

FourThought Financial held 421 shares of BioMarin Pharmaceuticals worth $36K as of Q3 2022.
FourThought Financial bought 266 BioMarin Pharmaceuticals shares in Q3 2022, an estimated $23.7K.
BioMarin Pharmaceuticals made up 0.01% of FourThought Financial's portfolio in Q3 2022, its #702 holding.
FourThought Financial first reported a position in BioMarin Pharmaceuticals in Q4 2020 and has held it in 8 quarters since.
FourThought Financial's BioMarin Pharmaceuticals position peaked at $75K in Q3 2021.
552 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q3 2022.

Based on FourThought Financial's 13F filing for Q3 2022, filed 21 Nov 2022.